LIDRISE Study: A Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops, Single Dose) in the Treatment of Acquired Blepharoptosis.
Clinical trial NCT06514612 · RECRUITING
Trial details
- NCT number
- NCT06514612
- Sponsor
- Santen SAS
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-12-30
- Primary completion
- 2026-08-01
- Enrollment
- 234
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.